Immune Ventures LLC has a total of 13 patent applications. Its first patent ever was published in 2016. It filed its patents most often in United States, Australia and Canada. Its main competitors in its focus markets pharmaceuticals and biotechnology are TIANJIN HENGJIA BIOTECHNOLOGY DEV CO LTD, SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RES INSTITUTE) and ALFACELL CORP.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 3 | |
#2 | Australia | 2 | |
#3 | Canada | 2 | |
#4 | EPO (European Patent Office) | 2 | |
#5 | WIPO (World Intellectual Property Organization) | 2 | |
#6 | Brazil | 1 | |
#7 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Moss David | 12 |
#2 | Tesi Raymond J | 12 |
#3 | Raymond J Tesi | 1 |
#4 | David Moss | 1 |
Publication | Filing date | Title |
---|---|---|
US2020397824A1 | In vivo priming of natural killer cells | |
CA3056631A1 | In vivo priming of natural killer cells | |
US2017071982A1 | In vivo priming of natural killer cells |